The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARQT | +137.53% | -14.02% | -2.98% | -9% |
| S&P | +14.5% | +93.32% | +14.09% | +108% |
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
The company released phase 3 trial results for an atopic dermatitis cream.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $81.50M | 164.1% |
| Gross Profit | $74.01M | 170.2% |
| Gross Margin | 90.81% | 2.0% |
| Market Cap | $1.67B | 55.2% |
| Market Cap / Employee | $4.89M | 0.0% |
| Employees | 342 | 15.5% |
| Net Income | -$15.89M | 69.6% |
| EBITDA | -$14.05M | 71.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $73.05M | -13.9% |
| Accounts Receivable | $106.69M | 145.8% |
| Inventory | 16.3 | 17.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $109.16M | -47.2% |
| Short Term Debt | $1.00M | 28.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -23.40% | 28.5% |
| Return On Invested Capital | -64.32% | -2.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.25M | 100.5% |
| Operating Free Cash Flow | $0.32M | 100.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.81 | 10.40 | 11.70 | 11.71 | 145.18% |
| Price to Sales | 8.33 | 8.85 | 9.26 | 6.76 | -22.28% |
| Price to Tangible Book Value | 6.01 | 11.10 | 12.45 | 13.24 | 169.55% |
| Enterprise Value to EBITDA | -27.45 | -226.11 | -88.02 | -120.98 | 505.90% |
| Return on Equity | -192.3% | -113.8% | -70.6% | -57.3% | -61.51% |
| Total Debt | $208.18M | $110.59M | $110.80M | $110.16M | -46.93% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
